AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 5 analysts
Fundamentals
Fundamentals institutional score is 97 using growth durability 96.7.
Valuation
Valuation institutional score is 35 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 78 using mean target upside 8.8%; dispersion penalty 3.8; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 24 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 3 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and analyst consensus provide support, while valuation and technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 21.0% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.96). Confidence: 90%.
Live forward EPS implies next-12-month EPS of ₹8.40. Applying the stock's normalized valuation corridor produces a fair range of ₹766.00 to ₹875.70, with base value near ₹809.26 (+49.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹8.40
Forward P/E
64.5x
Base Fair Value
₹809.26
Fair Range
₹766.00 - ₹875.70
Upside To Base
+49.3%
Estimate Source
Live forward EPS
Growth Estimate
+49.5%
5Y Average
98.19
Current
116.56
Overvalued
104.25
Undervalued
91.19
5Y Average
31.26
Current
37.11
Overvalued
34.28
Undervalued
29.62
5Y Average
6.56
Current
7.79
Overvalued
7.54
Undervalued
5.58
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 157.6x Premium | +85% vs avg | +10.2% |
ASTER DM QUALITY CARE LTD ASTERDMHospitals & Diagnostic Centres | +21.6% | 6.5% | 138.6x Premium | +63% vs avg | +47.9% |
NEPHROCARE HEALTH SERV L NEPHROPLUSHospitals & Diagnostic Centres | +21.2% | 7.7% | 87.3x Fair | +3% vs avg | +48.1% |
METROPOLIS HEALTHCARE LTD METROPOLISHospitals & Diagnostic Centres | +16.6% | 11.8% | 58.1x Undervalued | -32% vs avg | +7.6% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 54.5x Undervalued | -36% vs avg | +12.9% |
FORTIS HEALTHCARE LTD FORTISHospitals & Diagnostic Centres | +17.5% | 11.0% | 67.3x Undervalued | -21% vs avg | +1.4% |
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 46.9x Undervalued | -45% vs avg | +6.8% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 69.7x Undervalued | -18% vs avg | +6.9% |
DR AGARWALS HEALTH CARE L trades at a premium (116.6x vs peer avg 85.0x), implying higher growth or quality expectations from the Hospitals & Diagnostic Centres cohort. Peers include KRISHNA INST OF MED SCI L, ASTER DM QUALITY CARE LTD, NEPHROCARE HEALTH SERV L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹383 CrJun 2026Latest net profit
₹17 CrJun 2026Latest EPS
₹0.53Jun 2026Net margin
25.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 213 | 225 | 240 | 255 | 268 | 281 | 302 | 309 | 335 | 348 | 383 |
| Expenses + | 158 | 157 | 190 | 198 | 203 | 208 | 235 | 240 | 255 | 256 | 287 |
| Operating Profit | 55 | 67 | 49 | 58 | 65 | 73 | 67 | 69 | 80 | 92 | 96 |
| OPM % | 26% | 30% | 21% | 23% | 24% | 26% | 22% | 22% | 24% | 26% | 25% |
| Other Income + | 13 | 13 | 2 | 5 | 10 | 24 | 12 | 6 | 6 | 1 | 3 |
| Interest | 22 | 22 | 23 | 23 | 23 | 21 | 19 | 17 | 18 | 19 | 19 |
| Depreciation | 32 | 35 | 37 | 38 | 39 | 42 | 44 | 48 | 48 | 56 | 58 |
| Profit before tax | 15 | 24 | -8 | 1 | 12 | 34 | 16 | 10 | 20 | 18 | 22 |
| Tax % | 37% | 29% | 5% | 746% | 37% | 22% | 35% | 51% | 31% | 42% | 26% |
| Net Profit + | 10 | 17 | -9 | -4 | 8 | 27 | 10 | 5 | 14 | 11 | 17 |
| EPS in Rs | 0.25 | 0.84 | 0.32 | 0.15 | 0.44 | 0.33 | 0.53 | ||||
| Raw PDF | |||||||||||
| YOY Sales Growth % | 25.85% | 25.02% | 25.93% | 21.01% | 24.97% | 23.78% | 26.81% | ||||
| Material Cost % | 24.50% | 24.38% | 23.06% | 24.17% | 24.33% | 23.11% | 23.81% | 22.65% | 24.37% | 21.38% | 21.78% |
| Employee Cost % | 16.23% | 14.61% | 17.93% | 17.85% | 17.62% | 18.00% | 18.29% | 19.05% | 18.77% | 17.57% | 18.57% |
| Exceptional items | -1.20 | -2.87 | -2.83 | -6.73 | -0.71 | -3.21 | -0.71 | -0.72 | -0.71 | -4.91 | 0.00 |
| Other income normal | 14.61 | 16.19 | 5.01 | 11.39 | 10.48 | 26.93 | 13.03 | 6.81 | 7.11 | 6.21 | 3.42 |
| Exceptional items AT | -1 | -2 | -3 | -2 | -0 | -2 | -0 | -0 | -0 | -2 | 0 |
| Profit excl Excep | 10 | 19 | -6 | -1 | 8 | 29 | 10 | 5 | 15 | 13 | 17 |
| Profit for PE | 10 | 19 | -6 | -1 | 8 | 29 | 10 | 5 | 15 | 13 | 17 |
| Profit for EPS | 10 | 17 | -9 | -4 | 8 | 27 | 10 | 5 | 14 | 11 | 17 |
| YOY Profit Growth % | -22% | 55% | 274% | 512% | 80% | -57% | 60% |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Monitoring Agency Report